Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07726368
PHASE1

Study of ECC4703 With Sulfasalazine and Pitavastatin

Sponsor: Eccogene

View on ClinicalTrials.gov

Summary

Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide. ECC4703 is a potential new treatment for non-alcoholic fatty liver disease. The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.

Official title: A Phase 1, Open-Label, Fixed-Sequence, Single-Center, Two-Period, Drug-Drug Interaction Trial in Healthy Adult Participants to Evaluate the Effect of Steady-State ECC4703 on the Pharmacokinetics of Sulfasalazine (BCRP Probe Substrate) and Pitavastatin (OATP1B1/OATP1B3 Probe Substrate)

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-08-07

Completion Date

2026-12

Last Updated

2026-09-10

Healthy Volunteers

Yes

Interventions

DRUG

ECC4703

ECC4703 will be administered orally.

DRUG

Sulfasalazine

Sulfasalazine will be administered orally.

DRUG

Pitavastatin

Pitavastatin will be administered orally.

Locations (1)

Nucleus Network Pty Ltd

Melbourne, Victoria, Australia